New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center.

Fiche publication

Date publication

avril 2018

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VIGNAUD Jean-Michel

Tous les auteurs :
Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli V, Tazelaar H, Vignaud JM, Attanoos R, Beasley MB, Begueret H, Capron F, Chirieac L, Copin MC, Dacic S, Danel C, Foulet-Roge A, Gibbs A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain A, Kerr K, Marchevsky A, Nabeshima K, Picquenot JM, Rouquette I, Sagan C, Sauter J, Thivolet F, Travis WD, Tsao MS, Weynand B, Damiola F, Scherpereel A, Pairon JC, Lantuejoul S, Rusch V, Girard N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29723687

Résumé

The 2015 WHO classified malignant mesothelioma into epithelioid [EM], biphasic [BM] and sarcomatoid [SM] for prognostic relevance and treatment decisions. The survival of BM is suspected to correlate with the amount of the sarcomatoid component. The criteria for a sarcomatoid component and the interobserver variability between pathologists for identifying this component are not well described. In ambiguous cases, a "transitional"[TM] subtype has been proposed but was not accepted as a specific subtype in the 2015 WHO. The aims of this study was therefore to evaluate the interobserver agreement in the diagnosis of BM, to determine the nature and the significance of TM subtype and to relate the percentage of sarcomatoid component with survival. The value of BAP-1 staining and CDKN2A(p16) FISH were also assessed with respect to each of the tumoral components.